D.A. Davidson & CO. Has $91.60 Million Stake in Johnson & Johnson (NYSE:JNJ)

D.A. Davidson & CO. reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 0.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 552,320 shares of the company's stock after selling 3,006 shares during the period. Johnson & Johnson comprises 0.7% of D.A. Davidson & CO.'s investment portfolio, making the stock its 26th biggest position. D.A. Davidson & CO.'s holdings in Johnson & Johnson were worth $91,597,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Rosenberg Matthew Hamilton grew its position in shares of Johnson & Johnson by 5.2% in the first quarter. Rosenberg Matthew Hamilton now owns 2,989 shares of the company's stock valued at $496,000 after purchasing an additional 147 shares during the period. ZWJ Investment Counsel Inc. lifted its stake in shares of Johnson & Johnson by 1.4% during the first quarter. ZWJ Investment Counsel Inc. now owns 211,708 shares of the company's stock worth $35,110,000 after purchasing an additional 2,851 shares in the last quarter. Clark Asset Management LLC lifted its stake in shares of Johnson & Johnson by 5.6% during the first quarter. Clark Asset Management LLC now owns 5,859 shares of the company's stock worth $972,000 after purchasing an additional 310 shares in the last quarter. Smart Money Group LLC lifted its stake in shares of Johnson & Johnson by 6.5% during the first quarter. Smart Money Group LLC now owns 6,687 shares of the company's stock worth $1,109,000 after purchasing an additional 407 shares in the last quarter. Finally, Resonant Capital Advisors LLC lifted its stake in shares of Johnson & Johnson by 9.0% in the first quarter. Resonant Capital Advisors LLC now owns 28,653 shares of the company's stock worth $4,752,000 after acquiring an additional 2,366 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.2%

Shares of JNJ traded up $0.34 during mid-day trading on Friday, reaching $155.90. The company's stock had a trading volume of 3,482,521 shares, compared to its average volume of 8,059,757. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a market cap of $375.11 billion, a price-to-earnings ratio of 17.34, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The business has a fifty day moving average of $153.68 and a 200 day moving average of $154.09.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. Johnson & Johnson's dividend payout ratio is 57.84%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Wall Street Zen raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.